Tune in to our podcast for an in-depth discussion on immunotherapeutic strategies for Acute Myeloid Leukemia (AML). In this episode, we feature Dr Sarah Tettamanti, a senior scientist at the Fondazione Tettamanti Research Centre in Italy, who shares her expertise on CAR T-cell therapy for AML.
With host Dr Sarah de Vlieger, they examine the progress and challenges in treating AML with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies.
The episode also covers the complexities of the tumor microenvironment in AML, antigen selection for targeted therapy, and the design of smarter CAR T-cells. Sarah discusses the future of CAR T-cell therapy, including fourth-generation CAR T-cells and the role of natural killer cells in AML treatment.
Host: Dr Sarah de Vlieger
Guest: Dr Sarah Tettamanti
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe